VBIO News & Events

Valion Bio's wholly owned subsidiary, Velocity Bioworks, has entered into an exclusive commercial development and license agreement with LarmorBio for LarmorBio's BioScan-NMR platform, a next-generation nuclear magnetic resonance system. Under the agreement, Velocity Bioworks will host the first commercial deployment of the BioScan-NMR platform, with installation and commissioning at the company's San Antonio facility targeted for July 2026. Valion Bio secured the exclusive license and reference site arrangement at pre-institutional pricing, ahead of LarmorBio's pending Series A financing. The San Antonio installation, targeted for commissioning in July, is expected to anchor Velocity Bioworks' advanced diagnostics service offering and to serve as the demonstration and validation site for LarmorBio's broader commercial pipeline.

Valion Bio announced it has received the first study protocol under its previously announced non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health. Under the agreement, valued at up to $7M, NIAID will fully fund the in vivo studies required to support the company's Biologics License Application for Entolimod under the FDA's Animal Rule pathway, with the agency further committed to co-navigate the FDA submission process alongside Valion Bio upon favorable study outcomes. The protocol provided to Valion Bio is identical to a study design previously used and accepted by the FDA in support of a prior ARS medical countermeasure approval. This regulatory precedent meaningfully de-risks the design phase of the company's BLA-enabling work, as the agency has already accepted the structure as evidentiary under the Animal Rule. The studies will be conducted at the Armed Forces Radiobiology Research Institute, the U.S. government's primary radiological research facility for ARS countermeasure evaluation, with NIAID serving as the contracting and funding agency.

Valion Bio (VBIO) announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Lackey brings nearly two decades of combined scientific and legal experience across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built for Valion Bio's current phase of growth. Lackey joins from Alaunos Therapeutics (TCRT), where she served as Senior Vice President of Legal & Administration.